Aa
Boceprevir Pick-up.
Just got back from the Doctors and scored some BOC pills...first of all,these things are huge,bright blue in color.reminds me of them pills they had in the Matrix movie...i noticed something 15 minutes after taking my first 4 pills in the doc`s office,an awful taste in my mouth ,and i swallowed them down good....but the taste, yuk...i wonder if this is a good sign i got the real drugs ....anyone know bout that??....another thing im concerned about...the pills are obviously dyed blue...and im pretty sure it aint no organic natural color...proberly some blue # 30 synthetic food coloring...il die from food dye before the hep c...oh well...ya cant have your cake....or should i say ,pill and eat it too...
r.s
r.s
Yup... Waiting for the PCR results will be the tell all. BTW... My urine is turning blue, is yours? : )
also ....he will get the roll over into the open trial, if he dont clear by wk 12...all is not over...
I am sorry ...but we still dont know if its the taste or not...did you slide a pill open and take a small taste...?...try that...when i di it..its almost unbearable....still no proof tho...at least thats what i think...you said a year off work...im confused...you said you just started....try to taste the pill on the tonge
KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company also announced that it is developing a highly potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The compound, known as SCH 900518 is currently in Phase IIa clinical development. The update was presented today as part of the company's 2008 R&D Update meeting at its headquarters in Kenilworth, N.J.
"As pioneers in the hepatitis field, our vision is to apply our experience and innovation, as we have in the past, to continue to redefine and improve treatments for chronic hepatitis C, in the near term and in the future," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.
The company reported for the first time that in a Phase II study, a 48-week boceprevir regimen achieved an unprecedented 75 percent sustained virologic response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). This represents a near doubling of the 38 percent SVR 24 rate for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2) In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent. Importantly, for patients who received the boceprevir P/R lead-in regimen and had rapid virologic response (RVR), defined as undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment, SVR was 94 percent in the 48 week regimen and 82 percent in the 28-week regimen. RVR has been shown to be a reliable predictor for achieving SVR. These final results are from the HCV SPRINT-1 study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
----------------------------------------------------------------------------------------------------
Notice the RVR rate with 4 weeks of BOC.... SVR was 94 percent for 48 weeks and 82 percent for 28
"As pioneers in the hepatitis field, our vision is to apply our experience and innovation, as we have in the past, to continue to redefine and improve treatments for chronic hepatitis C, in the near term and in the future," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.
The company reported for the first time that in a Phase II study, a 48-week boceprevir regimen achieved an unprecedented 75 percent sustained virologic response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). This represents a near doubling of the 38 percent SVR 24 rate for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2) In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent. Importantly, for patients who received the boceprevir P/R lead-in regimen and had rapid virologic response (RVR), defined as undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment, SVR was 94 percent in the 48 week regimen and 82 percent in the 28-week regimen. RVR has been shown to be a reliable predictor for achieving SVR. These final results are from the HCV SPRINT-1 study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
----------------------------------------------------------------------------------------------------
Notice the RVR rate with 4 weeks of BOC.... SVR was 94 percent for 48 weeks and 82 percent for 28
Thanks so much for the link, hopefully he can do something else .He has been on the peg and riba for 78 weeks and we are no better off than when he started. Ruth
Hey, Everyone. My husband just started the boceprevir last week and doesn't have any bad/metallic taste problem. Boy, is he DISAPPOINTED! A year off work, all the regular
flu-like side effects, and not getting the trial drug after all. The taste problem sounds dreadful, but he'd still welcome it right now. Keep up the fight guys!!
flu-like side effects, and not getting the trial drug after all. The taste problem sounds dreadful, but he'd still welcome it right now. Keep up the fight guys!!
You are reading content posted in the Hepatitis Social Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
